AXS Investments LLC Acquires 2,016 Shares of Pfizer Inc. (NYSE:PFE)

AXS Investments LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,954 shares of the biopharmaceutical company’s stock after acquiring an additional 2,016 shares during the period. AXS Investments LLC’s holdings in Pfizer were worth $1,245,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of PFE. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in Pfizer by 98,197.9% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,948,438,709 shares of the biopharmaceutical company’s stock worth $71,468,732,000 after buying an additional 1,946,456,532 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Norges Bank acquired a new position in Pfizer during the 4th quarter worth $3,150,472,000. Wellington Management Group LLP lifted its holdings in Pfizer by 9.8% during the 1st quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock worth $8,932,423,000 after buying an additional 19,602,359 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Pfizer by 1,034.0% during the 1st quarter. Renaissance Technologies LLC now owns 12,149,955 shares of the biopharmaceutical company’s stock worth $495,718,000 after buying an additional 11,078,514 shares in the last quarter. 68.05% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.5 %

PFE stock traded up $0.15 during trading hours on Friday, reaching $29.92. 27,082,355 shares of the stock were exchanged, compared to its average volume of 31,586,170. The firm’s 50-day moving average is $31.97 and its 200-day moving average is $35.28. The company has a market cap of $168.94 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 1.91 and a beta of 0.63. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. Pfizer Inc. has a 12 month low of $28.93 and a 12 month high of $54.93.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.15. The firm had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $13.77 billion. Pfizer had a return on equity of 16.72% and a net margin of 15.30%. On average, equities research analysts expect that Pfizer Inc. will post 1.56 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Friday, November 10th will be issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 5.48%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 89.62%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wells Fargo & Company reduced their price objective on Pfizer from $39.00 to $35.00 and set an “equal weight” rating on the stock in a report on Monday, October 16th. UBS Group reissued a “neutral” rating and issued a $34.00 price target (down previously from $36.00) on shares of Pfizer in a research note on Friday, October 20th. Morgan Stanley cut their price target on Pfizer from $39.00 to $37.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 1st. Barclays cut their price target on Pfizer from $35.00 to $34.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 1st. Finally, BMO Capital Markets cut their price target on Pfizer from $44.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, October 16th. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $42.50.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.